SCHEMBL3089652

SCHEMBL3089652

NC(CS(=O)(=O)O)N1CCN(CCO)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 1/20 0.36
KMT2A Q03164 2/20 0.35
HTT P42858 2/20 0.35
LMNA P02545 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
MAPT P10636 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CYP3A4 P08684 2/20 0.32
TERT O14746 1/20 0.31
HSD11B1 P28845 1/20 0.31
MEN1 O00255 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
OPRD1 P41143 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2028838 0.94 CHRM2 (0.36) CHRM2CHRM1ALDH1A1KDM4EKMT2A
SCHEMBL5062396 0.81 CHRM2 (0.40) CHRM2CHRM1ALDH1A1KDM4EKMT2A
SCHEMBL4606042 0.79 CHRM2 (0.45) CHRM2CHRM1ALDH1A1KDM4EKMT2A
SCHEMBL3911963 0.79 CHRM2 (0.39) CHRM2CHRM1ALDH1A1KDM4EKMT2A
SCHEMBL6370319 0.79 KMT2A (0.42) CHRM2CHRM1ALDH1A1KDM4EKMT2A
SCHEMBL20495576 0.77 KMT2A (0.47) CHRM2CHRM1ALDH1A1KDM4EKMT2A
SCHEMBL72732 0.77 KMT2A (0.47) CHRM2CHRM1ALDH1A1KDM4EKMT2A
Water SCHEMBL20475938 0.76 KMT2A (0.46) CHRM2CHRM1ALDH1A1KDM4EKMT2A
Water SCHEMBL72731 0.76 KMT2A (0.46) CHRM2CHRM1ALDH1A1KDM4EKMT2A
Water SCHEMBL6936586 0.76 KMT2A (0.46) CHRM2CHRM1ALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6979442-B1 Stabilized protein compositions PFIZER INC. (US) 2005-12-27 US claimed
EP-3265558-B1 STABILIZED RNA SOLUTIONS BIO RAD LABORATORIES (US) 2020-05-06 EP disclosed
US-9896682-B2 Stabilized RNA solutions BIO-RAD LABORATORIES, INC. (US) 2018-02-20 US disclosed
EP-3265558-A1 STABILIZED RNA SOLUTIONS Bio-Rad Laboratories, Inc. (US) 2018-01-10 EP disclosed
WO-2016144891-A1 STABILIZED RNA SOLUTIONS BIO-RAD LABORATORIES, INC. (US) 2016-09-15 WO disclosed
US-20160257950-A1 STABILIZED RNA SOLUTIONS BIO-RAD LABORATORIES, INC. 2016-09-08 US disclosed
US-20140141089-A1 Nanoparticles, Compositions Thereof, and Methods of Use, and Methods of Making the Same COLORADO SCHOOL OF MINES (US) 2014-05-22 US disclosed
US-8496935-B2 Immunosuppressive polypeptides and nucleic acids PERSEID THERAPEUTICS LLC (US) 2013-07-30 US disclosed
US-8491899-B2 Immunosuppressive polypeptides and nucleic acids PERSEID THERAPEUTICS LLC (US) 2013-07-23 US disclosed
EP-2612868-A1 Immunosuppressive polypeptides and nucleic acids Perseid Therapeutics LLC (US) 2013-07-10 EP disclosed
US-6248353-B1 INCUBATION MEMBRANE PROTEIN WITH LIPOSOME DADE BEHRING INC. 2001-06-19 US disclosed
WO-2001041740-A2 RECONSTITUTION OF PURIFIED MEMBRANE PROTEINS INTO PREFORMED LIPOSOMES DADE BEHRING INC. (US) 2001-06-14 WO disclosed
US-6165981-A Stabilizing solutions for proteins and peptides DADE BEHRING INC. (US) 2000-12-26 US disclosed
EP-0988861-A1 Stabilized protein compositions Pfizer Products Inc. (US) 2000-03-29 EP disclosed
EP-0759074-B1 STABILIZING SOLUTIONS FOR TROPONIN DADE BEHRING INC (US) 1998-07-08 EP disclosed
EP-0565665-B1 PREPARATION OF PROTHROMBIN TIME REAGENTS FROM RECOMBINANT HUMAN TISSUE FACTOR AND SYNTHETIC PHOSPHOLIPIDS DADE INT INC (US) 1998-03-04 EP disclosed
US-5625036-A Preparation of prothrombin time reagents from recombinant human tissue factor and purified natural and synthetic phospholipids DADE INTERNATIONAL INC. (US) 1997-04-29 US disclosed
EP-0759074-A1 STABILIZING SOLUTIONS FOR PROTEINS AND PEPTIDES DADE INTERNATIONAL INC. (US) 1997-02-26 EP disclosed
WO-1996027661-A1 STABILIZING SOLUTIONS FOR PROTEINS AND PEPTIDES DADE INTERNATIONAL INC. (US) 1996-09-12 WO disclosed
WO-1993007492-A1 PREPARATION OF PROTHROMBIN TIME REAGENTS FROM RECOMBINANT HUMAN TISSUE FACTOR AND PURIFIED NATURAL AND SYNTHETIC PHOSPHOLIPIDS BAXTER DIAGNOSTICS INC. (US) 1993-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140141089-A1 Nanoparticles, Compositions Thereof, and Methods of Use, and Methods of Making the Same NPC1L1, LIPA, NPC1 CHRM2 4687/4885CHRM1 4813/4885ALDH1A1 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.